Brought to you by 
Metabolex grants Sanofi rights to Phase II diabetes candidate; deal ends
24 Feb 2023
Executive Summary
Metabolex Inc. (therapies for metabolic diseases) has granted Sanofi-Aventis exclusive worldwide rights to its MBX2982, a G-protein coupled receptor 119 (GPR119) agonist that is in Phase IIa trials for Type II diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Metabolex grants Sanofi rights to Phase II diabetes candidate; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice